(ADMA) ADMA Biologics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0008991046
Stock: Biologics, Therapeutics, Plasma, Antibodies
Total Rating 43
Risk 53
Buy Signal -0.45
| Risk 5d forecast | |
|---|---|
| Volatility | 53.7% |
| Relative Tail Risk | -10.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | -14.30 |
| Character TTM | |
|---|---|
| Beta | 0.863 |
| Beta Downside | 0.445 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.92% |
| CAGR/Max DD | 1.62 |
EPS (Earnings per Share)
Revenue
Description: ADMA ADMA Biologics March 04, 2026
ADMA Biologics, Inc. is a biopharmaceutical company specializing in plasma-derived therapies. It develops, manufactures, and commercializes treatments for immune deficiencies and infectious diseases. The companys operations include manufacturing facilities and plasma collection centers, crucial for sourcing raw materials for its products.
ADMAs product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) products for primary humoral immunodeficiency (PI), and Nabi-HB for Hepatitis B exposure. The biopharmaceutical sector often involves extensive research and development for such specialized treatments. The company also maintains a pipeline of new plasma-derived therapeutics.
ADMA distributes its products through various channels, including independent distributors and specialty pharmacies, a common model in the pharmaceutical industry for reaching diverse healthcare providers. Further research on ValueRay can provide deeper insights into ADMAs market position and financial performance.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 146.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -18.14 > 1.0 |
| NWC/Revenue: 77.81% < 20% (prev 64.69%; Δ 13.12% < -1%) |
| CFO/TA 0.08 > 3% & CFO 50.4m > Net Income 146.9m |
| Net Debt (-7.75m) to EBITDA (197.9m): -0.04 < 3 |
| Current Ratio: 6.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (243.9m) vs 12m ago -0.83% < -2% |
| Gross Margin: 57.39% > 18% (prev 0.51%; Δ 5687 % > 0.5%) |
| Asset Turnover: 91.68% > 50% (prev 87.27%; Δ 4.42% > 0%) |
| Interest Coverage Ratio: 26.69 > 6 (EBITDA TTM 197.9m / Interest Expense TTM 7.11m) |
Altman Z'' 4.46
| A: 0.64 (Total Current Assets 466.5m - Total Current Liabilities 69.5m) / Total Assets 624.2m |
| B: -0.26 (Retained Earnings -161.7m / Total Assets 624.2m) |
| C: 0.34 (EBIT TTM 189.8m / Avg Total Assets 556.5m) |
| D: -1.10 (Book Value of Equity -161.6m / Total Liabilities 146.9m) |
| Altman-Z'' Score: 4.46 = AA |
Beneish M -1.63
| DSRI: 2.65 (Receivables 158.4m/50.0m, Revenue 510.2m/426.5m) |
| GMI: 0.90 (GM 57.39% / 51.48%) |
| AQI: 0.72 (AQ_t 0.14 / AQ_t-1 0.19) |
| SGI: 1.20 (Revenue 510.2m / 426.5m) |
| TATA: 0.15 (NI 146.9m - CFO 50.4m) / TA 624.2m) |
| Beneish M-Score: -1.63 (Cap -4..+1) = CCC |
What is the price of ADMA shares?
As of March 04, 2026, the stock is trading at USD 16.38 with a total of 3,031,110 shares traded.
Over the past week, the price has changed by +5.54%, over one month by -6.51%, over three months by -16.94% and over the past year by +3.47%.
Over the past week, the price has changed by +5.54%, over one month by -6.51%, over three months by -16.94% and over the past year by +3.47%.
Is ADMA a buy, sell or hold?
ADMA Biologics has received a consensus analysts rating of 4.33.
Therefore, it is recommended to buy ADMA.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ADMA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.7 | 56.7% |
| Analysts Target Price | 25.7 | 56.7% |
ADMA Fundamental Data Overview March 04, 2026
P/E Trailing = 18.0217
P/E Forward = 28.9855
P/S = 7.7552
P/B = 8.5995
Revenue TTM = 510.2m USD
EBIT TTM = 189.8m USD
EBITDA TTM = 197.9m USD
Long Term Debt = 70.1m USD (from longTermDebt, two quarters ago)
Short Term Debt = 3.91m USD (from shortTermDebt, last quarter)
Debt = 79.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -7.75m USD (from netDebt column, last quarter)
Enterprise Value = 3.95b USD (3.96b + Debt 79.9m - CCE 87.6m)
Interest Coverage Ratio = 26.69 (Ebit TTM 189.8m / Interest Expense TTM 7.11m)
EV/FCF = 141.9x (Enterprise Value 3.95b / FCF TTM 27.8m)
FCF Yield = 0.70% (FCF TTM 27.8m / Enterprise Value 3.95b)
FCF Margin = 5.45% (FCF TTM 27.8m / Revenue TTM 510.2m)
Net Margin = 28.80% (Net Income TTM 146.9m / Revenue TTM 510.2m)
Gross Margin = 57.39% ((Revenue TTM 510.2m - Cost of Revenue TTM 217.4m) / Revenue TTM)
Gross Margin QoQ = 63.82% (prev 56.34%)
Tobins Q-Ratio = 6.33 (Enterprise Value 3.95b / Total Assets 624.2m)
Interest Expense / Debt = 2.04% (Interest Expense 1.63m / Debt 79.9m)
Taxrate = 19.83% (12.2m / 61.6m)
NOPAT = 152.1m (EBIT 189.8m * (1 - 19.83%))
Current Ratio = 6.71 (Total Current Assets 466.5m / Total Current Liabilities 69.5m)
Debt / Equity = 0.17 (Debt 79.9m / totalStockholderEquity, last quarter 477.3m)
Debt / EBITDA = -0.04 (Net Debt -7.75m / EBITDA 197.9m)
Debt / FCF = -0.28 (Net Debt -7.75m / FCF TTM 27.8m)
Total Stockholder Equity = 420.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 26.40% (Net Income 146.9m / Total Assets 624.2m)
RoE = 34.98% (Net Income TTM 146.9m / Total Stockholder Equity 420.1m)
RoCE = 38.72% (EBIT 189.8m / Capital Employed (Equity 420.1m + L.T.Debt 70.1m))
RoIC = 32.11% (NOPAT 152.1m / Invested Capital 473.8m)
WACC = 8.95% (E(3.96b)/V(4.04b) * Re(9.10%) + D(79.9m)/V(4.04b) * Rd(2.04%) * (1-Tc(0.20)))
Discount Rate = 9.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 3.88%
[DCF] Terminal Value 66.02% ; FCFF base≈60.9m ; Y1≈40.0m ; Y5≈18.2m
[DCF] Fair Price = 1.32 (EV 305.8m - Net Debt -7.75m = Equity 313.6m / Shares 238.0m; r=8.95% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 92.90 | EPS CAGR: 160.2% | SUE: 0.60 | # QB: 0
Revenue Correlation: 96.59 | Revenue CAGR: 51.78% | SUE: -0.13 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.25 | Chg7d=+0.020 | Chg30d=+0.020 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=1.04 | Chg7d=+0.100 | Chg30d=+0.100 | Revisions Net=+1 | Growth EPS=+58.4% | Growth Revenue=+25.0%
EPS next Year (2027-12-31): EPS=1.38 | Chg7d=+0.200 | Chg30d=+0.200 | Revisions Net=+1 | Growth EPS=+32.7% | Growth Revenue=+22.1%
P/E Forward = 28.9855
P/S = 7.7552
P/B = 8.5995
Revenue TTM = 510.2m USD
EBIT TTM = 189.8m USD
EBITDA TTM = 197.9m USD
Long Term Debt = 70.1m USD (from longTermDebt, two quarters ago)
Short Term Debt = 3.91m USD (from shortTermDebt, last quarter)
Debt = 79.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -7.75m USD (from netDebt column, last quarter)
Enterprise Value = 3.95b USD (3.96b + Debt 79.9m - CCE 87.6m)
Interest Coverage Ratio = 26.69 (Ebit TTM 189.8m / Interest Expense TTM 7.11m)
EV/FCF = 141.9x (Enterprise Value 3.95b / FCF TTM 27.8m)
FCF Yield = 0.70% (FCF TTM 27.8m / Enterprise Value 3.95b)
FCF Margin = 5.45% (FCF TTM 27.8m / Revenue TTM 510.2m)
Net Margin = 28.80% (Net Income TTM 146.9m / Revenue TTM 510.2m)
Gross Margin = 57.39% ((Revenue TTM 510.2m - Cost of Revenue TTM 217.4m) / Revenue TTM)
Gross Margin QoQ = 63.82% (prev 56.34%)
Tobins Q-Ratio = 6.33 (Enterprise Value 3.95b / Total Assets 624.2m)
Interest Expense / Debt = 2.04% (Interest Expense 1.63m / Debt 79.9m)
Taxrate = 19.83% (12.2m / 61.6m)
NOPAT = 152.1m (EBIT 189.8m * (1 - 19.83%))
Current Ratio = 6.71 (Total Current Assets 466.5m / Total Current Liabilities 69.5m)
Debt / Equity = 0.17 (Debt 79.9m / totalStockholderEquity, last quarter 477.3m)
Debt / EBITDA = -0.04 (Net Debt -7.75m / EBITDA 197.9m)
Debt / FCF = -0.28 (Net Debt -7.75m / FCF TTM 27.8m)
Total Stockholder Equity = 420.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 26.40% (Net Income 146.9m / Total Assets 624.2m)
RoE = 34.98% (Net Income TTM 146.9m / Total Stockholder Equity 420.1m)
RoCE = 38.72% (EBIT 189.8m / Capital Employed (Equity 420.1m + L.T.Debt 70.1m))
RoIC = 32.11% (NOPAT 152.1m / Invested Capital 473.8m)
WACC = 8.95% (E(3.96b)/V(4.04b) * Re(9.10%) + D(79.9m)/V(4.04b) * Rd(2.04%) * (1-Tc(0.20)))
Discount Rate = 9.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 3.88%
[DCF] Terminal Value 66.02% ; FCFF base≈60.9m ; Y1≈40.0m ; Y5≈18.2m
[DCF] Fair Price = 1.32 (EV 305.8m - Net Debt -7.75m = Equity 313.6m / Shares 238.0m; r=8.95% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 92.90 | EPS CAGR: 160.2% | SUE: 0.60 | # QB: 0
Revenue Correlation: 96.59 | Revenue CAGR: 51.78% | SUE: -0.13 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.25 | Chg7d=+0.020 | Chg30d=+0.020 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=1.04 | Chg7d=+0.100 | Chg30d=+0.100 | Revisions Net=+1 | Growth EPS=+58.4% | Growth Revenue=+25.0%
EPS next Year (2027-12-31): EPS=1.38 | Chg7d=+0.200 | Chg30d=+0.200 | Revisions Net=+1 | Growth EPS=+32.7% | Growth Revenue=+22.1%